These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30406948)

  • 1. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment.
    Roger JH; Bratton DJ; Mayer B; Abellan JJ; Keene ON
    Pharm Stat; 2019 Jan; 18(1):85-95. PubMed ID: 30406948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for composite estimands in confirmatory clinical trials: Examples from trials in nasal polyps and steroid reduction.
    Keene ON
    Pharm Stat; 2019 Jan; 18(1):78-84. PubMed ID: 30370691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment.
    Hartley B; Drury T; Lettis S; Mayer B; Keene ON; Abellan JJ
    Pharm Stat; 2022 May; 21(3):612-624. PubMed ID: 34997685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Missing data sensitivity analysis for recurrent event data using controlled imputation.
    Keene ON; Roger JH; Hartley BF; Kenward MG
    Pharm Stat; 2014; 13(4):258-64. PubMed ID: 24931317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.
    Claggett B; Pocock S; Wei LJ; Pfeffer MA; McMurray JJV; Solomon SD
    Circulation; 2018 Aug; 138(6):570-577. PubMed ID: 29588314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic.
    Cro S; Morris TP; Kahan BC; Cornelius VR; Carpenter JR
    BMC Med Res Methodol; 2020 Aug; 20(1):208. PubMed ID: 32787782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome.
    White IR; Joseph R; Best N
    J Biopharm Stat; 2020 Mar; 30(2):334-350. PubMed ID: 31718423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
    Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
    Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The attributable estimand: A new approach to account for intercurrent events.
    Darken P; Nyberg J; Ballal S; Wright D
    Pharm Stat; 2020 Sep; 19(5):626-635. PubMed ID: 32198954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation.
    Carpenter JR; Roger JH; Kenward MG
    J Biopharm Stat; 2013; 23(6):1352-71. PubMed ID: 24138436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple imputation for patient reported outcome measures in randomised controlled trials: advantages and disadvantages of imputing at the item, subscale or composite score level.
    Rombach I; Gray AM; Jenkinson C; Murray DW; Rivero-Arias O
    BMC Med Res Methodol; 2018 Aug; 18(1):87. PubMed ID: 30153796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A structured approach to choosing estimands and estimators in longitudinal clinical trials.
    Mallinckrodt CH; Lin Q; Lipkovich I; Molenberghs G
    Pharm Stat; 2012; 11(6):456-61. PubMed ID: 22962024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.
    Gao F; Liu GF; Zeng D; Xu L; Lin B; Diao G; Golm G; Heyse JF; Ibrahim JG
    Pharm Stat; 2017 Nov; 16(6):424-432. PubMed ID: 28834175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference-based sensitivity analysis for time-to-event data.
    Atkinson A; Kenward MG; Clayton T; Carpenter JR
    Pharm Stat; 2019 Nov; 18(6):645-658. PubMed ID: 31309730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinded continuous monitoring in clinical trials with recurrent event endpoints.
    Friede T; Häring DA; Schmidli H
    Pharm Stat; 2019 Jan; 18(1):54-64. PubMed ID: 30345693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.
    Ibrahim F; Tom BD; Scott DL; Prevost AT
    Trials; 2016 Jun; 17(1):272. PubMed ID: 27255212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials.
    Aaron SD; Fergusson D; Marks GB; Suissa S; Vandemheen KL; Doucette S; Maltais F; Bourbeau JF; Goldstein RS; Balter M; O'Donnell D; Fitzgerald M;
    Thorax; 2008 Feb; 63(2):122-8. PubMed ID: 17702790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.
    Rufibach K
    Pharm Stat; 2019 Mar; 18(2):145-165. PubMed ID: 30478869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using multiple imputation to estimate cumulative distribution functions in longitudinal data analysis with data missing at random.
    Dinh P
    Pharm Stat; 2013; 12(5):260-7. PubMed ID: 24019202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.